Evidence map›Paper›PMID 40670850›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study.

Ya Zheng, Zhaofeng Chen, Xiangyi Zan, Xidong Fang, Feifei Chen, Qian Ren, Yuping Wang, Qinghong Guo, Rui Ji, Yongning Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ya Zheng *Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Zhaofeng ChenDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Xiangyi Zan *Department of Geriatrics, Lanzhou University Second Hospital, Lanzhou, 730000, Gansu, China.
Xidong FangDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Feifei ChenDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Qian RenDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Yuping WangDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Qinghong GuoDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Rui JiDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Yongning ZhouDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China. zhouyn@lzu.edu.cn.ORCID 0000-0002-7304-929X

Funding

Fundamental Research Funds for the Central Universities lzujbky-2021-ct17Joint Scientific Research Fund of Gansu Province 23JRRA1487Lanzhou Science and Technology Program 2023-1-19Lanzhou Talent Innovation and Entrepreneurship Project 2019-RC-33Natural Science Foundation of Gansu Province 23JRRA0939
6 · The paper itself

Abstract

backgroundTFF2 is a promising yet underexplored biomarker for gastric cancer. We aimed to investigate the relationship between serum TFF2 and gastric cancer, including early gastric cancer, and its interactions with other factors.

methodsA cross-sectional, population-based study was conducted involving 3986 participants from Wuwei Cohort. The serum levels of TFF2, TFF1, TFF3, PG I, PG II, and Hp IgG were measured. Logistic regression and restricted cubic splines assessed associations and dose-response relationships.

resultsGastric cancer prevalence rose across serum TFF2 tertiles, from 1.6 to 5.0% (p for trend < 0.001). TFF2 demonstrated the strongest association with gastric cancer, with participants in the highest tertile showing over a fourfold increased risk (OR 4.02, 95% CI 2.25-7.19, p < 0.001) after adjusting for traditional risk factors and other biomarkers. The association remained robust for early gastric cancer, exhibiting over a threefold risk (OR 3.31, 95% CI 1.80-6.08, p < 0.001). RCS analyses confirmed dose-response relationships (p for non-linearity < 0.05). The joint analyses showed that participants in the highest tertiles of both TFF1 and TFF2, or in the lowest tertile of TFF1 and highest tertile of TFF2, had at least an eightfold increased risk of gastric cancer and early gastric cancer compared to those with both biomarkers in the lowest tertile.

conclusionSerum TFF2 is a more reliable biomarker for gastric cancer, including early gastric cancer, in the general population. Its strong dose-response association with gastric cancer outcomes and the synergistic effects with TFF1 highlight its potential to improve risk prediction and guide future research.

Indexed as

Biomarkers, TumorStomach NeoplasmsTrefoil Factor-2AdultAgedCross-Sectional StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRisk FactorsTrefoil Factor-1Biomarkers, TumorTFF2 protein, humanTrefoil Factor-1Trefoil Factor-2BiomarkerEarly gastric cancerGastric cancerTFF2

Identifiers

PMID40670850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.